Lava Therapeutics announces updated data from Phase 1/2a trial of LAVA-051

Lava Therapeutics announced a poster presentation highlighting updated data, including safety, pharmacodynamics and pharmacokinetics from the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsing/refractory chronic lymphocytic leukemia and multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022. The presentation included initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts. In addition to the favorable safety profile demonstrated as of the data cutoff, LAVA-051 showed predictable and linear pharmacokinetics and on-mechanism pharmacodynamic parameters consistent with Vgamma9Vdelta2-T cell engagement, including increasing occupancy of patient Vgamma9Vdelta2-T cells with LAVA-051 and consistent increases in the expression of T-cell activation markers.